Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vaxil Bio Ltd VXLLF


Primary Symbol: V.VXL

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > Vaxart Announces Publication of Complete Data from Preclinic
View:
Post by bligicka on Nov 17, 2021 8:58am

Vaxart Announces Publication of Complete Data from Preclinic

Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases......... at least Vaxart shares it's data with its shareholders......Goren promised to share the data from USAMRIID experiment but never did ....that is my biggest beef with Goren... and the news release leak which caused me huge losses
Be the first to comment on this post
Vaxil Bio Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities